Addex Therapeutics reported net income of -$2.19M for the quarter ended Mar 2026. This income statement covers 31 quarters of results from Dec 2017 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2017 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 6.32M | 7.53M | 0.62M | 0.82M | 0.89M | ||||||||||||||||||||||||||
| Revenue & cost | |||||||||||||||||||||||||||||||
| Revenue | 1.09M | 0.74M | 3.42M | 0.26M | 0.19M | 0.42M | 0.61M | 0.54M | 0.70M | 0.37M | 0.17M | 0.27M | 0.13M | 0.06M | 0.00M | 0.04M | 310.29 | ||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 4.09M | -3.12M | -3.79M | -4.08M | 5.97M | -2.86M | 4.19M | -0.28M | -0.32M | -0.56M | -0.17M | -0.28M | -0.38M | -236.05M | -0.07M | -173.58M | -283.19M | -285.43M | -0.07M | -46.14M | |||||||||||
| Selling, General & AdministrativeSG&A | 2.03M | -1.60M | -1.28M | -2.43M | 1.59M | -1.88M | 1.92M | -0.66M | -0.82M | -0.67M | -0.83M | -0.89M | -0.75M | -0.55M | -0.44M | -0.58M | -0.65M | -0.65M | -0.93M | -0.58M | |||||||||||
| Other Operating ExpensesOther Opex | -8.85M | 0.00 | -21.33M | 321.11 | -2.02M | -2.29 | 235.82M | -2.13M | 173.41M | 282.91M | 285.14M | 46.09M | |||||||||||||||||||
| Operating ExpensesOpex | 6.12M | -4.72M | -13.93M | -6.50M | 7.56M | -4.75M | -15.22M | -0.94M | -1.14M | -1.22M | -3.01M | -1.17M | -1.12M | -0.79M | -2.64M | -0.75M | -0.93M | -0.93M | -0.99M | -0.62M | |||||||||||
| Operating IncomeOp. Inc | -4.94M | -3.89M | -16.82M | -6.24M | -7.36M | -4.31M | -21.30M | -0.40M | -0.44M | -0.85M | -2.53M | -0.90M | -0.99M | -0.72M | -3.14M | -0.67M | -0.89M | -0.87M | -0.97M | -0.61M | |||||||||||
| EBIT | -4.94M | -3.89M | -16.82M | -6.24M | -7.36M | -4.31M | -21.30M | -0.40M | -0.44M | -0.85M | -2.53M | -0.90M | -0.99M | -0.72M | -3.14M | -0.67M | -0.89M | -0.87M | -0.97M | -0.61M | |||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.03M | -0.01M | -0.01M | -0.07M | 0.13M | 0.06M | -0.16M | -0.03M | -0.15M | 0.03M | -0.20M | -0.00M | -0.96M | -0.01M | 0.01M | -0.02M | 0.01M | -1.02M | -0.00M | -0.00M | |||||||||||
| Interest & Investment IncomeInt & Inv Inc | -0.18M | -0.01M | 0.17M | 0.10M | 212.85 | 0.00M | -0.29M | 0.03M | 0.01M | 0.02M | -0.29M | 0.06M | -0.03M | -0.02M | 0.03M | -0.02M | 0.00M | -0.00M | -0.00M | -0.00M | |||||||||||
| Net income details | |||||||||||||||||||||||||||||||
| EBT | -5.14M | -3.92M | -4.80M | -6.31M | -7.50M | -4.25M | 6.59M | -0.40M | -0.58M | -0.80M | -1.01M | -842.08 | -1.61M | -1.76M | -1.36M | -1.64M | -2.37M | -1.97M | -2.29M | -2.19M | |||||||||||
| Tax ProvisionsTaxes | -0.01 | -0.01 | 0.02 | -0.01 | -0.02 | 0.05 | |||||||||||||||||||||||||
| Profit After TaxPAT | -5.14M | -3.92M | -16.65M | -6.31M | -7.50M | -4.25M | -21.60M | -2.60M | -2.98M | -2.96M | -11.90M | -3.54M | -0.01 | -1.77M | -9.43M | -1.64M | -0.02 | -1.97M | -2.30M | -2.19M | |||||||||||
| Equity Income | -0.59M | -1.01M | -0.88M | -0.94M | -1.49M | -1.10M | -1.32M | -1.57M | |||||||||||||||||||||||
| Income from Non-Controlling InterestsInc. Minority | 0.14M | 0.09M | -0.08M | 0.72M | 0.50M | 0.14M | -0.01M | -0.03M | -0.15M | -0.03M | -0.36M | -0.06M | |||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -5.14M | -3.92M | -4.80M | -6.31M | -7.50M | -4.25M | 6.59M | -0.40M | -0.58M | -0.80M | -1.01M | -842.08 | -1.61M | -1.76M | -1.36M | -1.64M | -2.37M | -1.97M | -2.29M | -2.19M | |||||||||||
| Income from Discontinued OperationsIncome (Discontinued) | -0.00M | -2.40M | -2.16M | -9.08M | -0.00M | 15.85M | -2.77M | -0.02M | 0.14M | 147.05M | -4.26M | ||||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -5.14M | -3.92M | -4.80M | -6.31M | -7.50M | -4.25M | 6.59M | -0.40M | -2.98M | -2.96M | -10.09M | -0.00M | 14.24M | -4.53M | -1.38M | -1.64M | -2.22M | 145.08M | -6.55M | -2.19M | |||||||||||
| Income towards Parent CompanyParent Net Inc | -5.14M | -3.92M | 18.36M | -6.31M | -7.50M | -4.25M | 5.10M | -0.40M | -2.98M | -2.96M | 1.29M | -0.00M | 14.24M | -4.53M | 11.05M | -1.64M | -2.22M | 145.08M | -6.55M | -2.19M | |||||||||||
| Net Income towards Common StockholdersNet Income | 0.14M | 0.09M | 18.36M | 0.72M | 0.50M | 0.14M | 5.10M | -0.03M | -0.15M | -0.03M | 1.29M | -0.06M | 14.24M | -4.53M | 11.05M | 0.07M | -2.22M | 145.08M | -6.55M | -2.19M | |||||||||||
| Additional items | |||||||||||||||||||||||||||||||
| EPS (Basic) | 0.33 | 0.21 | 33.90 | 1.33 | 0.92 | 0.25 | 7.11 | -0.05 | -0.21 | -0.04 | 1.09 | -0.05 | 12.07 | -3.84 | 7.09 | 0.05 | -1.43 | 93.16 | -3.85 | -1.28 | |||||||||||
| EPS (Diluted) | 1.09 | -0.05 | 12.07 | -3.84 | 7.09 | 0.05 | -1.43 | 93.16 | -3.85 | -1.28 | |||||||||||||||||||||
| Shares Outstanding | 0.42M | 0.42M | 0.54M | 0.54M | 0.54M | 0.54M | 0.72M | 0.72M | 0.72M | 0.72M | 1.18M | 1.18M | 1.18M | 1.18M | 1.56M | 1.56M | 1.56M | 1.56M | 1.70M | 1.70M | |||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.18M | 1.18M | 1.18M | 1.18M | 1.56M | 1.56M | 1.56M | 1.56M | 1.70M | 1.70M | |||||||||||||||||||||
| EBITDA | -4.94M | -3.89M | -16.82M | -6.24M | -7.36M | -4.31M | -21.30M | -0.40M | -0.44M | -0.85M | -2.53M | -0.90M | -0.99M | -0.72M | -3.14M | -0.67M | -0.89M | -0.87M | -0.97M | -0.61M | |||||||||||
| Interest ExpensesInt Expense | 0.03M | -0.01M | -0.01M | -0.07M | 0.13M | 0.06M | -0.16M | -0.03M | -0.15M | 0.03M | -0.20M | -0.00M | -0.96M | -0.01M | 0.01M | -0.02M | 0.01M | -1.02M | -0.00M | -0.00M | |||||||||||
| Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |